An open label, randomized, three period, single-dose, crossover study to determine the bioavailability of 300 mg aliskiren mini-tablets relative to the 300 mg aliskiren market tablet under fasted condition and to evaluate the effect of food on the pharmacokinetics of 300 mg aliskiren minitablets in healthy subjects

简要总结

主要结局

次要结局

• To evaluate the safety and tolerability of a single oral dose of 300 mg aliskiren mini-tablets administered with or without meal and a single oral dose of 300 mg aliskiren market tablet in healthy subjects without meal, respectively.(Number Of AEs From First Dosing To End Of Study Evaluation And Number Of SAEs From Date Of ICF To 4weeks After Last Dose Administration. Safety assessments will also include vital signs, blood pressure and pulse rate) standard clinical laboratory evaluations. Blood pressure, pulse rate: screening*, each baseline*, pre- dose* and 2, 4, 12 and 24* hours post dose, end of study* Note: measurements are supine, or supine and after 3 min standing if indicated by an *asterisk) Hematology; Blood chemistry; Urinalysis: screening, each baseline, end of study)